Search clinical trials for: Adenovirus Vector

Total 3160 results

Tenaya Therapeutics
Medical University of South Carolina; Johns Hopkins University; University of... and other collaborators

Recruiting

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (RIDGE)

Arrhythmogenic Right Ventricular Cardiomyopathy

United States, Italy, United Kingdom, France, Sweden, Germany
CanSino Biologics Inc.

Recruiting

A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years

Herpes Zoster

Canada
Zhongnan Hospital
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of...

Recruiting

A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes

COVID-19

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Clinical Study of SARS-CoV-2 Vaccine in Metabolism-related Fatty Liver Disease

Metabolic Associated Fatty Liver Disease
Wuhan BravoVax Co., Ltd.
National University Hospital, Singapore; Shanghai BravoBio Co., Ltd.

Not yet recruiting

Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine

COVID-19

Singapore
Ankara City Hospital Bilkent
The Scientific and Technological Research Council of Turkey; MonitorCRO

Recruiting

Phase I Clinical Trial With New SARS-CoV-2 CoVacHGMix Type 5 Adenoviral Vector Vaccine

COVID-19

Turkey
Zhejiang Provincial Center for Disease Control...

Recruiting

Sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine

Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization

China
Gamaleya Research Institute of Epidemiology and...

Not yet recruiting

Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray (SPRAY)

COVID-19 | SARS-CoV-2 Acute Respiratory Disease
Fundación Huésped
CanSino Biologics Inc.; Canadian Center for Vaccinology; Hospital Fernandez

Recruiting

Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older. (COVID-19)

Covid19

Argentina
Eli Lilly and Company
Incyte Corporation

Recruiting

A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)

Rheumatoid Arthritis

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

Healthy Volunteer

United States
NPO Petrovax
CanSino Biologics Inc.

Completed

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

Covid19

Russian Federation
National Institute of Allergy and Infectious Diseases...

Completed

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

Ebola Disease | Immunisation

United States
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
Emergent BioSolutions

Completed

A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

Anthrax Infection

United States
Janssen Vaccines & Prevention B.V.
Bavarian Nordic GmbH

Terminated

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Hemorrhagic Fever, Ebola

France, United Kingdom, Kenya, United States, Uganda, Burkina Faso, Tanzania
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
Herantis Pharma Plc.

Active, not recruiting

Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE) (AdeLE)

Secondary Lymphedema

Finland, Sweden
Crucell Holland BV

Completed

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
CanSino Biologics Inc.

Completed

IH Convidecia as Second Booster Dose Against Breakthrough Infections

COVID-19

Malaysia
Janssen Vaccines & Prevention B.V.
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaborators

Completed

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

Healthy

United States, South Africa, Thailand, Uganda, Rwanda
CanSino Biologics Inc.

Withdrawn

A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine

COVID-19
CanSino Biologics Inc.
Beijing Institute of Biotechnology

Withdrawn

Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)

COVID-19
CanSino Biologics Inc.
Beijing Institute of Biotechnology

Terminated

A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents

COVID-19

Chile
CanSino Biologics Inc.
Beijing Institute of Biotechnology

Completed

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

COVID-19

Mexico, Argentina, Chile, Pakistan, Russian Federation
Institute of Biotechnology, Academy of Military...
Zhongnan Hospital

Completed

A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults

COVID-19

China
Institute of Biotechnology, Academy of Military...
Zhongnan Hospital; Jiangsu Province Centers for Disease Control and Prevention and other collaborators

Completed

A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV)

COVID-19

China
University of Oxford
GlaxoSmithKline; European Commission; Oxford University Hospitals NHS Trust; ReiThera...

Completed

Class II Invariant Chain HCV Vaccine Study

Hepatitis C

United Kingdom
Herantis Pharma Plc.

Terminated

A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema

Secondary Lymphedema

Finland
International Vaccine Institute
Heidelberg University; International Centre for Diarrhoeal Disease Research... and other collaborators

Active, not recruiting

Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines

Covid19

Madagascar, Mozambique
Seventh Medical Center of PLA General Hospital

Active, not recruiting

Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.

COVID-19

China
CanSino Biologics Inc.
Jiangsu Province Centers for Disease Control and Prevention; Beijing Institute...

Completed

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

COVID-19

China
CanSino Biologics Inc.
Jiangsu Province Centers for Disease Control and Prevention

Completed

A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.

COVID-19

China
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC; Targovax ASA

Completed

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Colorectal Cancer | Ovarian Cancer | Appendiceal Cancer

United States
National Institute of Allergy and Infectious Diseases...
US Military HIV Research Program

Completed

Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults

Ebola Virus

Uganda
CanSino Biologics Inc.
Jiangsu Province Centers for Disease Control and Prevention; Beijing Institute...

Completed

A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

COVID-19

China
National Taiwan University Hospital
Taoyuan General Hospital, Ministry of Health and Welfare,Taoyuan,Taiwan

Completed

Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination

Healthy Adult Volunteers

Taiwan
Jiangsu Province Centers for Disease Control and...

Active, not recruiting

Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming With an Inactivated SARS-CoV-2 Vaccine

COVID-19

China
Albert B. Sabin Vaccine Institute
ICON plc; Oklahoma Blood Institute

Completed

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

Ebola Virus Disease | Marburg Virus Disease

United States
Janssen Vaccines & Prevention B.V.
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Completed

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo (EBOVAC-Salone)

Ebola Virus Disease

Sierra Leone
Jiangsu Province Centers for Disease Control and...

Completed

Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults

COVID-19

China
Jiangsu Province Centers for Disease Control and...

Completed

The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine

Adenovirus Type-5 Vectored COVID-19 Vaccine

China
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; Centre Muraz and other collaborators

Completed

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Hemorrhagic Fever, Ebola

Kenya, Uganda, Burkina Faso, Côte D'Ivoire
Janssen Vaccines & Prevention B.V.
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Hemorrhagic Fever, Ebola

United States, Uganda, Kenya, Mozambique, Nigeria, Tanzania
Janssen Vaccines & Prevention B.V.
Bavarian Nordic

Terminated

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Human Papillomavirus Infections

United States, Belgium
National Institute of Allergy and Infectious Diseases...

Completed

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Terminated

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

HIV Infections

United States, Peru
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

HIV Infections

United States

Search clinical trials for: Adenovirus Vector

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations